Technical Analysis for XNCR - Xencor, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical XNCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 3.49% | |
| Earnings Movers | Other | 3.49% | |
| Outside Day | Range Expansion | 3.49% | |
| Below Lower BB | Weakness | 3.49% | |
| Down 3 Days in a Row | Weakness | 3.49% | |
| Lower Bollinger Band Touch | Weakness | 3.49% | |
| MACD Bearish Signal Line Cross | Bearish | -0.33% | |
| Expansion Pivot Sell Setup | Bearish Swing Setup | -0.33% | |
| Earnings Movers | Other | -0.33% | |
| Gapped Down | Weakness | -0.33% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/24/2020
- Sector: Healthcare
- Industry: Biotechnology
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions through XmAb technology platform. The company's engineered antibodies that are in development include XmAb5871, a B-cell inhibitor that is in Phase Ib/IIa clinical trials for the treatment of autoimmune diseases, such as rheumatoid arthritis and lupus; XmAb7195, an IgE inhibitor to treat severe asthma and allergic diseases; and XmAb5574/MOR208, a Cytotoxic B-cell depleting product candidate for the treatment of B-cell cancers. It has a collaboration agreement with Boehringer Ingelheim International GmbH; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. The company was founded in 1997 and is based in Monrovia, California.
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Autoimmune Diseases Immune System Monoclonal Antibodies Antibody Rheumatoid Arthritis Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement
Medicine Biotechnology Biopharmaceutical Cancer Medical Specialties Life Sciences Immunology Antibodies Autoimmune Diseases Immune System Monoclonal Antibodies Antibody Rheumatoid Arthritis Glycoproteins Treatment Of Autoimmune Diseases Lupus Boehringer Ingelheim Immunoglobulin E Manufacturing Services Agreement
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 46.33 |
| 52 Week Low | 27.75 |
| Average Volume | 288,680 |
| 200-Day Moving Average | 36.92 |
| 50-Day Moving Average | 36.06 |
| 20-Day Moving Average | 35.22 |
| 10-Day Moving Average | 35.42 |
| Average True Range | 1.56 |
| ADX | 15.34 |
| +DI | 12.01 |
| -DI | 27.02 |
| Chandelier Exit (Long, 3 ATRs ) | 32.59 |
| Chandelier Exit (Short, 3 ATRs ) | 36.37 |
| Upper Bollinger Band | 37.92 |
| Lower Bollinger Band | 32.53 |
| Percent B (%b) | -0.08 |
| BandWidth | 15.32 |
| MACD Line | -0.49 |
| MACD Signal Line | -0.19 |
| MACD Histogram | -0.3066 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 36.28 | ||||
| Resistance 3 (R3) | 36.61 | 35.55 | 35.58 | ||
| Resistance 2 (R2) | 35.55 | 34.48 | 35.38 | 35.34 | |
| Resistance 1 (R1) | 33.82 | 33.83 | 33.29 | 33.49 | 35.11 |
| Pivot Point | 32.76 | 32.76 | 32.50 | 32.59 | 32.76 |
| Support 1 (S1) | 31.03 | 31.69 | 30.50 | 30.70 | 29.07 |
| Support 2 (S2) | 29.97 | 31.04 | 29.80 | 28.84 | |
| Support 3 (S3) | 28.24 | 29.97 | 28.60 | ||
| Support 4 (S4) | 27.91 |
